Home NDC 53002-2540 Cephalexin
Product NDC 53002-2540
11-digit product format 530022540
Labeler code 53002
Product ID 53002-2540_bc53ef7e-3d8b-4fef-99eb-3b8d3509aac8
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name Cephalexin
Dosage form POWDER, FOR SUSPENSION
Route ORAL
Labeler RPK Pharmaceuticals, Inc.
Application ANDA062703
Marketing category ANDA
Marketing start 1990-09-30
Marketing end 0000-00-00
Substance CEPHALEXIN
Active strength 250 mg/5mL
Pharmacologic classes Cephalosporin Antibacterial [EPC],Cephalosporins [CS]
NDC exclude flag No
Listing certified through 2021-12-31
Current FDA listing Historical FDA.report record Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 33 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Package NDC Code Status Snapshot Source SHA-256 2025-12-14 17:58 UTC · source 2025-12-05 excluded product product I Inactivated by FDA d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 53002-2540-1 I Inactivated by FDA d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 53002-2540-2 I Inactivated by FDA d630ba8d3edf…732f749b63fb…2025-08-27 00:01 UTC · source 2025-08-26 excluded product product I Inactivated by FDA f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 53002-2540-1 I Inactivated by FDA f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 53002-2540-2 I Inactivated by FDA f5e01cc5f278…a2eaf40c39c3…2025-04-01 02:39 UTC · source 2025-03-31 excluded product product I Inactivated by FDA 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 53002-2540-1 I Inactivated by FDA 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 53002-2540-2 I Inactivated by FDA 2ef7874e63bc…57b86245f4fa…2025-03-28 20:22 UTC · source 2025-03-28 excluded product product I Inactivated by FDA a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 53002-2540-1 I Inactivated by FDA a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 53002-2540-2 I Inactivated by FDA a1b67e2a42f9…c4cf2c586c0d…2025-03-22 03:12 UTC · source 2025-03-21 excluded product product I Inactivated by FDA cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 53002-2540-1 I Inactivated by FDA cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 53002-2540-2 I Inactivated by FDA cfe11265f3b6…090c488252e2…2025-03-10 12:48 UTC · source 2025-03-10 excluded product product I Inactivated by FDA cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 53002-2540-1 I Inactivated by FDA cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 53002-2540-2 I Inactivated by FDA cdf11ea48f46…ba0047e9e063…2025-02-02 03:52 UTC · source 2025-01-31 excluded product product U Excluded because listing certification expired 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 53002-2540-2 U Excluded because listing certification expired 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 53002-2540-1 U Excluded because listing certification expired 302b2466d912…e7b80fea0513…2025-01-20 13:05 UTC · source 2025-01-20 excluded product product U Excluded because listing certification expired ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 53002-2540-2 U Excluded because listing certification expired ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 53002-2540-1 U Excluded because listing certification expired ed331223b511…672a5bd82f5f…2025-01-11 03:41 UTC · source 2025-01-10 excluded product product U Excluded because listing certification expired 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 53002-2540-2 U Excluded because listing certification expired 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 53002-2540-1 U Excluded because listing certification expired 0efc9e666f02…f202fb6c5f17…2020-12-18 03:04 UTC · source 2020-12-17 excluded product product I Inactivated by FDA e2bbac7714bc…27bdfed8d636…2020-12-18 03:04 UTC · source 2020-12-17 excluded package package 53002-2540-1 I Inactivated by FDA e2bbac7714bc…27bdfed8d636…2020-12-18 03:04 UTC · source 2020-12-17 excluded package package 53002-2540-2 I Inactivated by FDA e2bbac7714bc…27bdfed8d636…2020-06-10 20:45 UTC · source 2020-06-10 excluded product product I Inactivated by FDA 9bebd1f3094a…5416666fcb17…2020-06-10 20:45 UTC · source 2020-06-10 excluded package package 53002-2540-1 I Inactivated by FDA 9bebd1f3094a…5416666fcb17…2020-06-10 20:45 UTC · source 2020-06-10 excluded package package 53002-2540-2 I Inactivated by FDA 9bebd1f3094a…5416666fcb17…
Source provenance: Browse the complete Orange Book source catalog · source snapshot 42 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date A062703-001 CEPHALEXIN CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 A062703-002 CEPHALEXIN CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 2 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 3 · 84 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-08-18 06:07:40 2026-07 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 caaa826d4ba7…2026-08-18 06:07:40 2026-07 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 d06236e962d9…2024-10-29 15:01 UTC 2024-10 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 4b0b4de00fa7…2022-04-04 05:41 UTC 2022-04 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 A062703-001 CEPHALEXIN EQ 125MG BASE/5ML FOR SUSPENSION / ORAL AB 1987-02-13 bb7c543d1eb4…2022-03-09 01:35 UTC 2022-03 A062703-002 CEPHALEXIN EQ 250MG BASE/5ML FOR SUSPENSION / ORAL AB RS 1987-02-13 bb7c543d1eb4…
Observed Orange Book normalized TE history# Normalized TE history page 1 of 3 · 84 observed states.
DailyMed Product Concepts# FDA-Initiated Inactive NDC Indexing# NDC, Effective, Related label table NDC Effective Related label 53002-2540-1 2025-01-30 These highlights do not include all the information needed to use CEPHALEXIN safely and effectively. See full prescribing information for CEPHALEXIN. CEPHALEXIN capsules, and CEPHALEXIN for oral suspension, for oral use Initial U.S. Approval: 1971 53002-2540-2 2025-01-30 These highlights do not include all the information needed to use CEPHALEXIN safely and effectively. See full prescribing information for CEPHALEXIN. CEPHALEXIN capsules, and CEPHALEXIN for oral suspension, for oral use Initial U.S. Approval: 1971 53002-2540-1 2023-06-07 These highlights do not include all the information needed to use CEPHALEXIN safely and effectively. See full prescribing information for CEPHALEXIN. CEPHALEXIN capsules, and CEPHALEXIN for oral suspension, for oral use Initial U.S. Approval: 1971 53002-2540-2 2023-06-07 These highlights do not include all the information needed to use CEPHALEXIN safely and effectively. See full prescribing information for CEPHALEXIN. CEPHALEXIN capsules, and CEPHALEXIN for oral suspension, for oral use Initial U.S. Approval: 1971 53002-2540-1 2023-01-30 These highlights do not include all the information needed to use CEPHALEXIN safely and effectively. See full prescribing information for CEPHALEXIN. CEPHALEXIN capsules, and CEPHALEXIN for oral suspension, for oral use Initial U.S. Approval: 1971 53002-2540-2 2023-01-30 These highlights do not include all the information needed to use CEPHALEXIN safely and effectively. See full prescribing information for CEPHALEXIN. CEPHALEXIN capsules, and CEPHALEXIN for oral suspension, for oral use Initial U.S. Approval: 1971 53002-2540-1 2020-12-15 These highlights do not include all the information needed to use CEPHALEXIN safely and effectively. See full prescribing information for CEPHALEXIN. CEPHALEXIN capsules, and CEPHALEXIN for oral suspension, for oral use Initial U.S. Approval: 1971 53002-2540-2 2020-12-15 These highlights do not include all the information needed to use CEPHALEXIN safely and effectively. See full prescribing information for CEPHALEXIN. CEPHALEXIN capsules, and CEPHALEXIN for oral suspension, for oral use Initial U.S. Approval: 1971 53002-2540-1 2020-01-31 These highlights do not include all the information needed to use CEPHALEXIN safely and effectively. See full prescribing information for CEPHALEXIN. CEPHALEXIN capsules, and CEPHALEXIN for oral suspension, for oral use Initial U.S. Approval: 1971 53002-2540-2 2020-01-31 These highlights do not include all the information needed to use CEPHALEXIN safely and effectively. See full prescribing information for CEPHALEXIN. CEPHALEXIN capsules, and CEPHALEXIN for oral suspension, for oral use Initial U.S. Approval: 1971
DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 53002-2540-1 Cephalexin 100 mL in 1 BOTTLE POWDER, FOR SUSPENSION 100 8 53002-2540-2 Cephalexin 200 mL in 1 BOTTLE POWDER, FOR SUSPENSION 200 8
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 53002-2540 CEPHALEXIN CAPSULE CEPHALEXIN POWDER, FOR SUSPENSION [RPK PHARMACEUTICALS, INC.] 8 Legacy NDC, 2 package rows 20230609_3b1a58b4-8a3f-4053-ad60-eff02200b178.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 3 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 53002-2540-1 53002254001 100 mL in 1 BOTTLE (53002-2540-1) 100 ml 2018-10-01 0000-00-00 No No Current 53002-2540-2 53002254002 200 mL in 1 BOTTLE (53002-2540-2) 200 ml 2018-10-01 0000-00-00 No No Current